Citius Oncology, Inc. (CTOR)

Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Net Income	-23.08	-21.15	-12.7	-10.87
Stock-Based Compensation	7.39	7.5	1.97	-
Other Operating Activities	0.7	0.58	0.58	1.15
Change in Inventory	-8.25	-2.13	-	-
Change in Accounts Payable	5.67	2.42	1.2	0.18
Change in Other Net Operating Assets	17.7	12.91	8.96	9.53
Operating Cash Flow	0.13	0.13	-	-
Sale (Purchase) of Intangibles	-5	-5	-	-
Investing Cash Flow	-5	-5	-	-
Long-Term Debt Issued	-	3.8	-	-
Net Debt Issued (Repaid)	3.8	3.8	-	-
Other Financing Activities	1.07	1.07	-	-
Financing Cash Flow	4.87	4.87	-	-
Net Cash Flow	0	0	-	-
Levered Free Cash Flow	-1.26	-1.94	4.55	-
Unlevered Free Cash Flow	-1.26	-1.94	4.55	-
Change in Net Working Capital	-10.34	-8.42	-10.16	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q